Telavancin: A novel lipoglycopeptide

Clinical Infectious Diseases

Volumn 49, Issue 12, 2009, Pages 1908-1914

  Saravolatz, Louis D ^a,b,d   Stein, Gary E ^c   Johnson, Leonard B ^a,b,d  

^a Medical Center   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DAPTOMYCIN; MOXIFLOXACIN; PEPTIDOGLYCAN; POLYPEPTIDE ANTIBIOTIC AGENT; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN; VIBATIV;

BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HOT FLUSH; HUMAN; KIDNEY FAILURE; MEMBRANE DEPOLARIZATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PAIN; PRIORITY JOURNAL; PRURITUS; QT INTERVAL; REVIEW; SIDE EFFECT; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS AUREUS; TASTE DISORDER; URINE; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VOMITING;

EID: 72049133154     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648438     Document Type: Review

References (40)

1. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998; 42:1303-1304
2. Pakyz AL, MacDougall C, Oinenen M, Polk, RE. Trends in antibacterial use in US academic health centers. Arch Intern Med 2008; 168:2254-2260
3. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in nonvancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible cinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 60:788-794
4. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-2402
5. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent antiinfective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004; 53:797-803. (Pubitemid 38660281)
6. Printseveskaya SS, Pavlov AY, Olsufyeva EN, et al. Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria. J Med Chem 2002; 45:1340-1347
7. Leadbetter MR, Adams SM, Bazzini B, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) 2004; 57:326-336 (Pubitemid 38811717)
8. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:1127-1134 (Pubitemid 40327734)
9. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52:2383-2388 (Pubitemid 351915666)
10. Saravolatz L, Pawlak J, Johnson L, Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2007; 60:406-409 (Pubitemid 47243894)
11. Goldstein EJ, Citron DM, Merriam CV, Warren YV, Tyrell KL, Fernandez HT. In vitro activities of the new semisynthetic glycopepetide telavancin (TD-6424), vancomycin, daptomycin, linezolid and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 2004; 48:2149-2152
12. Leuthner KD, Cheung CM, Rybak MJ, Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin- resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58:338-343
13. Kaniga K, Blosser RS, Karloswsky JA, Sahm DF. In vitro activity of telavancin (TD-6424) against Bacillus anthracis [abstract E 2010]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). 2004.
14. Leonard SN, Vidaillac C, Rybak M. Activity of telavancin against Staphylococcus aureus strains wth various vancomycin susceptibilties in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2009; 53:2928-2933
15. Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005; 49:195-201. (Pubitemid 40065793)
16. Wong SL, Barriere SL, Kitt MM, Goldberg MR. Multiple dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 2008; 62:780-783
17. Pankuch GA, Appelbaum PC. Postantibiotic effects of telavancin against 16 Gram-positive organisms. Antimicrob Agents Chemother 2009; 53:1275-1277
18. Sun HK, Duchin K, Nightengale CH, et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006; 50:788-790 (Pubitemid 43191003)
19. Gotfried MH, Shaw JP, Benton BM, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother 2008; 52:92-97
20. LodiseTP Jr, Gotfried M, Barriere S, Drusano GL Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2008; 52:2300-2304 (Pubitemid 351915656)
21. Duchin K, Shaw J, Seroogy J, et al. Single dose pharmacokinetics of telavancin in subjects with renal dysfunction [abstract pl028]. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Disease (Prague, Czech Republic). 2004.
22. Duchin K, Shaw J, Seroogy J, et al. Effect of hemodialysis on single dose pharmacokinetics of telavancin [abstract P 897]. In: Program and abstracts of the 15th European Congress of Clinical Microbiology and Infectious Disease (Copenhagen, Denmark). 2005.
23. Patel JH, Grio MC, Churchwell MD, Seroogy J, Barriere S, Mueller BA. Telavancin transmembrane clearance during in vitro continuous venovenous hemofiltration [abstract pl539]. In: Program and abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases (Nice, France). 2007.
24. Wong SL, Shaw JP, Barriere SL, et al. Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment [abstract A-1951]. In program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). 2006.
25. Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 3602-3604
26. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin- resistant Staphyloccus aureus. J Antimicrob Chemother 2006; 58:1177-1184 (Pubitemid 44884136)
27. Hegde SS, Reyes N, Wiens, T et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004; 48:3043-3050 (Pubitemid 38989173)
28. Odenholt I, Lowdin E, Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother 2007; 51:3311-3316
29. Reyes N, Skinner R, Benton BM, et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58:462-465 (Pubitemid 44294968)
30. Hegde SS, Difuntorum S, Skinner R Trumbull J, Krause KM. Efficacy of telavancin agasint glycopeptides-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J Antimicrob Chemother 2009; 63:763-766
31. Reyes N, Skinner R, Kaniga K, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 4344-4346 (Pubitemid 41400983)
32. Madrigal AG, Basuino L, Chambers HF. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:3163-3165 (Pubitemid 41060554)
33. Stucki A, Gerber P, Acosta F, et al. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 2006; 50:770-773
34. Yin LJ, Calhoun JH, Thomas TS, Wirtz ED. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis; studies with a rabbit model. J Antimicrob Chemother 2009; 63: 357-360
35. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococi in a biofilm model. J Antimicrob Chemother 2005; 56: 337-343 (Pubitemid 41158522)
36. Clouse FL, Hovde LB, Rotschaffer JC. In vitro evaluation of the activities of telavancin, cefazolin and vancomycin against methicillinsusceptible and methicillin resistant Staphylococcus aureus in peritoneal dialysate. Antimicrob Agents Chemother 2007; 51:4521-4524
37. Stryjewski ME, Graham DR, Wilson Se, et al. Assessment of telavancin in complicated skin and skin structure infections study. Clin Infect Dis 2008; 46:1683-1693
38. Rubinstein E, Corey GR, Boucher HW, et al. Telavancin for the treatment of hospital- acquired pneumonia in severely ill and older patients: the ATTAIN studies [abstract K-529]. In Program and abstracts of the 46th ICAAC/IDSA annual meeting. 2008.
39. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004; 44:689-695 (Pubitemid 38765930)
40. Laohavaleeson S, Barriere SL, Nicolau DP, et al. Cost effectiveness of telavancin vs. vancomycin for the treatment of complicated skin and skin structure infections. Pharmacotherapy 2008; 28:1471-1482